Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 45Breast Neoplasms 20Myelodysplastic Syndromes 19Prostatic Neoplasms 12Neoplasms 12Leukemia, Myelomonocytic, Chronic 12Carcinoma, Hepatocellular 10Stomach Neoplasms 9Recurrence 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Multiple Myeloma 6Lung Neoplasms 6Myeloproliferative Disorders 5Melanoma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Biphenotypic, Acute 4Leukemia 4Cholangiocarcinoma 4

Interventions

toripalimab 1Injections 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Malignant Solid Tumors × Injections × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡